56 completed, 5 terminated, 3 withdrawn, 2 unknown. 31 Phase 3, 30 Phase 2, 4 Phase 1, 4 Phase 4, 1 Early Phase 1.
Follow Vehicle gel: new trials by email Literature Review of Vehicle gel trials Research Report on Vehicle gel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients Vehicle gel, SR-T100 gel with 1.0% of SM, SR-T100 gel with 2.3% of SM - Common Wart | Phase 2 | Suspended | G&E Herbal Biotechnology Co., LTD | 102 | 2030-09-01 | 2023-09-14 |
| Randomized, Triple-Blind, Vehicle-Controlled Trial of Topical Dapsone Gel 7.5% in Patients With Acne Vulgaris Dapsone 7.5% gel, Vehicle gel - Acne Vulgaris | Phase 4 | Completed | Oya Helin Dundar | 100 | 2025-06-17 | 2026-05-22 |
| A Study of GR1014 Cutaneous Gel for the Prevention of Skin Reactions Caused by Radiation Therapy for Breast Cancer GR1014-CG 2.4%, Vehicle Gel, Radiation Therapy - Radiodermatitis; Acute | Phase 2 | Active not recruiting | Graegis Pharmaceuticals Ltd | 273 | 2024-07-26 | 2025-09-25 |
| Transient Receptor Potential Channels TRPM8 Agonist, TRPV1 Agonist, TRPV4 Agonist - Aging | Early Phase 1 | Enrolling by invitation | Penn State University | 45 | 2024-07-17 | 2026-07-27 |
| A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VYN201 Gel in Subjects With Non-segmental Vitiligo. VYN201 Gel, Vehicle Gel - Non-segmental Vitiligo | Phase 2 | Terminated | Vyne Therapeutics Inc. | 205 | 2024-06-04 | 2026-04-21 |
| Efficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome Patidegib Topical Gel, Patidegib Topical Gel with no active patidegib - Gorlin Syndrome | Phase 3 | Completed | Sol-Gel Technologies, Ltd. | 113 | 2024-03-17 | 2026-09-18 |
| A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis SM-020 gel 1.0%, Vehicle gel - Seborrheic Keratosis | Phase 2 | Unknown | DermBiont, Inc. | 60 | 2023-11-06 | 2024-05-10 |
| Eyelid Androgen Treatment in Dry Eye Testosterone gel 4.5%, Vehicle gel - Aqueous Tear Deficiency, Meibomian Gland Dysfunction of Bilateral Eyes (Disorder) | Phase 2 | Completed | Southern California College of Optometry at Marshall B. Ketchum University | 24 | 2023-04-02 | 2025-05-25 |
| Study of TP-04 in Participants With Papulopustular Rosacea Lotilaner Gel, 2.0%, Vehicle control gel - Papulopustular Rosacea | Phase 2 | Completed | Tarsus Pharmaceuticals, Inc. | 37 | 2023-03-01 | 2023-11-24 |
| Randomized and Open Label Study for Safety and Efficacy of DBI-102 vs. Vehicle vs. Hydroquinone on Skin Pigmentation and Lentigos DBI-102, Vehicle gel, Hydroquinone Cream - Hyperpigmentation | Phase 2 | Completed | DermBiont, Inc. | 75 | 2022-08-18 | 2023-10-25 |
| Study of the Efficacy and Safety of Granexin® Gel to Improve Burn Wound Healing Granexin® gel (200 μM), Vehicle gel - Second Degree Burn, Thermal Burn | Phase 2 | Withdrawn | Xequel Bio, Inc. | 2022-08-01 | 2023-06-22 | |
| NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) NFX-179 gel, Vehicle gel - Cutaneous Neurofibroma, Neurofibromatosis 1 | Phase 2 | Completed | NFlection Therapeutics, Inc. | 199 | 2021-09-29 | 2026-02-17 |
| CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea CGB-400, Vehicle Gel - Rosacea | Phase 2 | Completed | CAGE Bio Inc. | 78 | 2021-05-07 | 2026-04-01 |
| Acetylated Natural Nucleotides in Treating Hand-foot Syndrome Gel containing Acetylated Natural Nucleotides, Vehicle Gel - Hand-foot Syndrome | Not applicable | Completed | Nan xu | 21 | 2020-11-03 | 2023-03-01 |
| A Phase 3 Molluscum Contagiosum Efficacy and Safety Study SB206 10.3% berdazimer, vehicle gel - Molluscum Contagiosum | Phase 3 | Completed | Novan, Inc. | 891 | 2020-09-01 | 2023-01-26 |
| NFX-179 Topical Gel Treatment in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) NFX-179 Gel, Vehicle Gel - Neurofibromatosis 1, Cutaneous Neurofibroma | Phase 2 | Completed | NFlection Therapeutics, Inc. | 48 | 2020-08-21 | 2022-08-09 |
| A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery Granexin® gel 100 μM, Granexin® gel 200 μM, Vehicle gel - Mammoplasty, Scarring | Phase 2 / Phase 3 | Completed | Xequel Bio, Inc. | 184 | 2020-07-01 | 2022-06-06 |
| Safety and Tolerability Study of Cerdulatinib Gel, 0.37% in Adults With Vitiligo Cerdulatinib 0.37% gel, Vehicle gel - Vitiligo | Phase 2 | Completed | Dermavant Sciences GmbH | 33 | 2019-09-27 | 2020-11-24 |
| A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC SB206 12%, Placebo - Molluscum Contagiosum | Phase 3 | Completed | Novan, Inc. | 355 | 2019-06-13 | 2023-03-23 |
| A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1) SB206 12%, Placebo - Molluscum Contagiosum | Phase 3 | Completed | Novan, Inc. | 352 | 2019-06-03 | 2022-12-27 |
Showing 20 of 69. Sign in to see all of them.
Acne Vulgaris (18) · Keratosis, Actinic (15) · Diabetic Foot (4) · Molluscum Contagiosum (4) · Rosacea (4) · Basal Cell Nevus Syndrome (3) · Pain (3) · Carcinoma, Basal Cell (2) · Cicatrix (2) · Diabetes Complications (2) · Diabetes Mellitus (2) · Erythema (2) · Foot Ulcer (2) · Neurofibromatosis 1 (2) · Vitiligo (2)
Novan, Inc. (11) · LEO Pharma (7) · Peplin (6) · G&E Herbal Biotechnology Co., LTD (4) · Galderma R&D (4) · Stiefel, a GSK Company (3) · Xequel Bio, Inc. (3) · DermBiont, Inc. (2) · GlaxoSmithKline (2) · NFlection Therapeutics, Inc. (2) · PellePharm, Inc. (2) · Amryt Research Limited (1) · Aponia Laboratories, Inc. (1) · Balmoral Medical company (1) · Bausch & Lomb Incorporated (1)
United States (44) · Canada (11) · France (7) · Australia (6) · United Kingdom (6) · Germany (5) · Spain (3) · Belize (2) · Brazil (2) · Dominican Republic (2) · Hungary (2) · India (2) · Italy (2) · Taiwan (2) · Argentina (1)
Joyce Rico, MD (4) · Hamm-Ming Sheu, MD (2) · Adelaide Hebert, MD (1) · Amy Paller, MD (1) · Andrew Pollack, MD (1) · Angela Moore, MD (1) · Ashu Rastogi, MD (1) · Ayse Esra Koku Aksu, MD, Prof. (1) · C. William Hanke, MD (1) · Carlos Sanabria, MD (1) · Catherine Mrs Queille-Roussel, MD (1) · Cheng-Yang Chou, M.D. (1) · Claus Garbe, MD (1) · Daniel M Siegel, MD (1)
PMID 22417254, PMID 34909721, PMID 24934963, PMID 25584134, PMID 27672413, PMID 31186047, PMID 35587172, PMID 35830173, PMID 36287306, PMID 37184839, PMID 42205007
2015 (2), 2016 (2), 2023 (2), 2017 (1)